Bicycle Therapeutics Reports Q3 2026 Financials and Receives FDA Orphan Drug Designation

Bicycle Therapeutics plc (NASDAQ: BCYC) released its third-quarter 2026 financial results and business updates on October 29, 2026. The company reported a net loss of $10.5 million for the three months ended September 30, 2026, or $(0.15) per share, a significant improvement compared to a net loss of $59.1 million, or $(0.85) per share, in the same period of the prior year.

Collaboration revenue for the quarter totaled $34.1 million, a sharp increase from $11.7 million in the prior year. This rise was attributed to the recognition of all remaining revenue under the company’s collaboration with Bayer Consumer Care AG following the termination of the underlying agreement. Conversely, research and development (R&D) expenses decreased to $33.4 million from $58.4 million, driven by lower clinical program costs and workforce reductions announced in 2025 and 2026. General and administrative expenses also declined to $14.1 million from $18.9 million.

As of September 30, 2026, the company held $469.9 million in cash and cash equivalents, down from $628.1 million at the end of 2025. The company stated that this cash balance provides runway into 2030.

On the clinical front, Bicycle Therapeutics announced that nuzefatide pevedotin, a Bicycle Drug Conjugate targeting EphA2, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The designation, which applies to therapies for diseases affecting fewer than 200,000 patients in the U.S., provides incentives including tax credits for qualified clinical trial costs, exemptions from certain FDA user fees, and potential seven years of market exclusivity upon approval.

The company is actively enrolling patients in a Phase 2 clinical trial for nuzefatide in recurrent pancreatic ductal adenocarcinoma (PDAC) and expects to provide further updates in 2027. Additionally, Bicycle Therapeutics plans to initiate its first company-sponsored radioligand clinical trial for BT1702, an MT1-MMP-targeting Bicycle Radioconjugate, in the second half of 2027.